Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? - Wikidata - wikimedia - TriplyDB

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

http://www.wikidata.org/entity/Q35022487

about

Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity Cellular target genes of Epstein-Barr virus nuclear antigen 2.Monoclonal antibodies in the treatment of chronic lymphoid leukemias.Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction CAMPATH: from concept to clinic.Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.

P2860

Q33415472-FA7F7591-7E13-46FA-AA32-612B32491DAD Q35101342-8B64141C-4BDF-4A9B-834E-573BD9C1DD89 Q35752823-8BD29A78-DEC0-4A15-864B-F201C3EFBEC2 Q35781773-32C066C8-B3FF-40E3-8B46-F005E740E969 Q36251298-CB7D2052-4991-4632-8CAA-6C7D1D3CD6B6 Q36284521-238C64E6-49EA-4E7B-BAEC-BB321ED911B3 Q36832113-EFF0BFBC-4353-4CB1-8482-E3051DC1C2F2 Q46763767-E842E6E4-4651-40B4-A41C-0A0AAA5832DD Q46798255-ED85B8EC-C853-4793-9B98-443DD008475F

P2860

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

http://www.wikidata.org/entity/Q35022487

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@ast

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@en

type

label

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@ast

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@en

prefLabel

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@ast

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@en

P1433

Q35022487-7ACE00B7-59EC-4CE1-8B5F-D8B95FC9CB97

P1476

Q35022487-17740386-69E6-413F-8D23-46B7F6A995C6

P2093

Q35022487-77FE0019-7AF9-4D55-83EB-A1717DA3B595

Q35022487-A057487C-4FDD-4CE6-B27B-39766EB611E2

Q35022487-AD238E51-67DF-4DBA-B8E2-FA2ECBA92F09

Q35022487-E4F578F3-AD7A-46A3-BF10-6887826D3952

Q35022487-F094926A-8278-4DA8-98E3-DD7FE5037EFA

P2860

Q35022487-106C39C3-46D7-4836-94AA-FE8815986BAA

Q35022487-226FF094-4628-42DA-9ECC-85672883B17B

Q35022487-2322C1A9-4F17-4EA1-A512-9A8671BE2BE0

Q35022487-2C3DCFA9-D934-4F1B-8713-26F9D1CC83F4

Q35022487-41643111-911D-4EA8-A782-4EF25AE95F37

Q35022487-49AB65A8-FE8E-4D2A-9811-8DDF147FB741

Q35022487-5B046E0A-2E78-4208-ABD7-6908E88CF419

Q35022487-5D0AACCB-8A9D-4FA8-B066-106B31373244

Q35022487-5E35897F-F4E3-4057-8267-158126D28363

Q35022487-76AB2EDE-94F0-4F05-B058-0548D53BF83D

P2888

Q35022487-99DCF0A5-1D2C-49C1-B007-5500081773F5

P304

Q35022487-8C6DE7EF-B49A-4025-9A19-18467F737D0D

P31

Q35022487-0BD8F4A3-F626-4EB5-BB21-6F3F6C701EFE

P356

Q35022487-C99761FA-CD0C-423E-B672-8606065F9FD3

P407

Q35022487-42BAC961-5060-4A4B-A742-60E7D0D943FF

P433

Q35022487-274F6B7E-0245-4A5C-88E4-1A7CCE7A0853

P478

Q35022487-87E32D10-CAD6-48FF-BFFC-668AD6241744

P50

Q35022487-43084A4F-E70B-480F-9B03-1D82F566D53F

P577

Q35022487-967BDC5B-CC09-491F-9122-7935A54A7CD0

P5875

Q35022487-C8F78162-3459-488E-8BD2-95D77B656247

P698

Q35022487-3ACB9DE9-CDBC-4277-BF18-4D63DAA44695

P356

P1433

Bone Marrow Transplantation

P1476

Alemtuzumab (Campath-1H) for t ...... nonmyeloablative conditioning?

@en

P2093

G Hale

http://www.w3.org/2001/XMLSchema#string

J M Goldman

http://www.w3.org/2001/XMLSchema#string

S Giralt

http://www.w3.org/2001/XMLSchema#string

S Mackinnon

http://www.w3.org/2001/XMLSchema#string

S Slavin

http://www.w3.org/2001/XMLSchema#string

P2860

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Reshaping human antibodies for therapy

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.

CD34: to select or not to select? That is the question.

Role of interleukin-7 in T-cell development from hematopoietic stem cells.

The CD52 antigen and development of the CAMPATH antibodies.

Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?

Metabolism and action of purine nucleoside analogs.

PBSC mobilization, collection and positive selection in patients with chronic lymphocytic leukemia.

P2888

P304

797-804

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1703733

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Herman Waldmann

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10996438

http://www.w3.org/2001/XMLSchema#string

P698

12476271

http://www.w3.org/2001/XMLSchema#string